PMID- 21509161
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20231105
IS  - 2005-9256 (Electronic)
IS  - 1598-2998 (Print)
IS  - 1598-2998 (Linking)
VI  - 43
IP  - 1
DP  - 2011 Mar
TI  - Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for 
      Non-small Cell Lung Cancer.
PG  - 32-41
LID - 10.4143/crt.2011.43.1.32 [doi]
AB  - PURPOSE: To evaluate treatment outcomes and prognostic factors in non-small cell 
      lung cancer (NSCLC) patients treated with concurrent chemoradiation. MATERIALS 
      AND METHODS: From January 2005 to June 2009, 51 patients were treated with 
      concurrent chemoradiation for 3 different aims: locally advanced stage III, 
      locally recurrent disease, and postoperative gross residual NSCLC. Median age was 
      63 years. Distribution of stages by the 6th edition of American Joint Committee 
      on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemotherapy was 
      administered every week concurrently with radiation using one of the following 
      regimens: paclitaxel (60 mg/m(2)), docetaxel+cisplatin (20 mg/m(2)+20 mg/m(2)), 
      cisplatin (30 mg/m(2)). Total radiation dose was 16-66.4 Gy (median, 59.4 Gy). 
      RESULTS: Median follow-up duration was 40.8 months. The overall response rate was 
      84.3% with 23 complete responses. The median survival duration for the overall 
      patient group was 17.6 months. The 3-year survival rate was 17.8%. A total of 21 
      patients had recurrent disease at the following sites: loco-regional sites 
      (23.6%), distant organs (27.5%). In the multivariate analysis of the overall 
      patient group, a clinical tumor response (p=0.002) was the only significant 
      prognostic factor for overall survival (OS). In the multivariate analysis of the 
      definitive chemoradiation arm, the use of consolidation chemotherapy (p=0.022), 
      biologically equivalent dose (BED)(10) (p=0.007), and a clinical tumor response 
      (p=0.030) were the significant prognostic factors for OS.The median survival 
      duration of the locally recurrent group and the postoperative gross residual 
      group were 26.4 and 23.9 months, respectively. CONCLUSION: Our study demonstrated 
      that clinical tumor response was significantly associated with OS in the overall 
      patient group. Further investigations regarding the optimal radiation dose in the 
      definitive chemoradiation and the optimal treatment scheme in locally recurrent 
      NSCLC would be required.
FAU - Lee, Dong-Soo
AU  - Lee DS
AD  - Department of Radiation Oncology, The Catholic University of Korea School of 
      Medicine, Seoul, Korea.
FAU - Kim, Yeon-Sil
AU  - Kim YS
FAU - Kang, Jin-Hyoung
AU  - Kang JH
FAU - Lee, Sang-Nam
AU  - Lee SN
FAU - Kim, Young-Kyoun
AU  - Kim YK
FAU - Ahn, Myung-Im
AU  - Ahn MI
FAU - Han, Dae-Hee
AU  - Han DH
FAU - Yoo, Ie-Ryung
AU  - Yoo IeR
FAU - Wang, Young-Pil
AU  - Wang YP
FAU - Park, Jae-Gil
AU  - Park JG
FAU - Yoon, Sei-Chul
AU  - Yoon SC
FAU - Jang, Hong-Seok
AU  - Jang HS
FAU - Choi, Byung-Oak
AU  - Choi BO
LA  - eng
PT  - Journal Article
DEP - 20110331
PL  - Korea (South)
TA  - Cancer Res Treat
JT  - Cancer research and treatment
JID - 101155137
EIN - Cancer Res Treat. 2011 Jun;43(2):139
PMC - PMC3072533
OTO - NOTNLM
OT  - Concurrent chemoradiation
OT  - Non-small cell lung cancer
OT  - Prognostic factor
OT  - Recurrent non-small cell lung cancer
COIS- Conflict of interest relevant to this article was not reported.
EDAT- 2011/04/22 06:00
MHDA- 2011/04/22 06:01
PMCR- 2011/03/01
CRDT- 2011/04/22 06:00
PHST- 2010/05/06 00:00 [received]
PHST- 2010/06/22 00:00 [accepted]
PHST- 2011/04/22 06:00 [entrez]
PHST- 2011/04/22 06:00 [pubmed]
PHST- 2011/04/22 06:01 [medline]
PHST- 2011/03/01 00:00 [pmc-release]
AID - 10.4143/crt.2011.43.1.32 [doi]
PST - ppublish
SO  - Cancer Res Treat. 2011 Mar;43(1):32-41. doi: 10.4143/crt.2011.43.1.32. Epub 2011 
      Mar 31.